On August 1 2023, PFIZER INC ($NYSE:PFE) revealed their financial results for the second quarter of FY2023: total revenue of USD 12.7 billion, a decrease of 54.1% from the same quarter in the previous year, and net income of USD 2.3 billion, which is a drop of 76.5% compared to the same quarter in the prior year.
Pfizer Inc. reported its earnings results for the second quarter of fiscal year 2023 on August 1. On Tuesday, the stock opened at $35.9 and closed at $35.6, down 1.2% from its prior closing price of 36.1. The decline can be attributed to a decrease in demand and sales for its products due to the ongoing pandemic. The decline in net income was mainly due to a fall in product sales and higher costs associated with research and development activities.
Overall, while the revenue figures were promising, the net income was somewhat lower than expected. The company has taken several steps to improve its financial performance, such as restructuring operations and optimizing its supply chain, but it remains to be seen if these measures will be effective in the long run. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Pfizer Inc. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Pfizer Inc. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Pfizer Inc. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Pfizer Inc are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Pfizer Inc Stock Fair Value Calculator
At GoodWhale, we conducted a deep dive analysis of PFIZER INC‘s financials. Through our proprietary Valuation Line, we calculated the intrinsic value of PFIZER INC’s share to be around $54.3. Currently, PFIZER INC stock is traded at $35.6, representing a 34.4% discount from its intrinsic value. This implies that the stock is undervalued at the moment and there is a potential for significant gains in the future. More…
Risk Rating Analysis
Star Chart Analysis
In the pharmaceutical industry, competition is fierce between companies striving to bring innovative new drugs to market. Among the leaders in this industry are Pfizer Inc and its competitors Astellas Pharma Inc, Roche Holding AG, and AstraZeneca PLC. While each company has its own strengths and weaknesses, they all share a commitment to research and development in an effort to stay ahead of the competition.
– Astellas Pharma Inc ($TSE:4503)
Astellas Pharma Inc is a Japanese pharmaceutical company with a market cap of 3.61T as of 2022. The company’s ROE is 6.6%. Astellas Pharma is engaged in the research, development, manufacture, and marketing of pharmaceutical products. The company’s products include ethical drugs, over-the-counter drugs, and generic drugs. Astellas Pharma also has a clinical research division that conducts clinical trials of new drugs.
Roche Holding AG is a multinational pharmaceutical company headquartered in Basel, Switzerland. The company was founded in 1896 by Fritz Hoffmann-La Roche. Roche is the world’s largest biotech company, with products in the areas of pharmaceuticals, diagnostics, and consumer health. The company’s mission is to “improve lives by enabling people to do more, feel better, and live longer.”
Roche Holding AG has a market cap of 270.34B as of 2022, a Return on Equity of 47.83%. The company’s strong market position and financial performance are due to its innovative products and services, which address a broad range of medical needs. Roche is committed to research and development, and has a strong pipeline of new products in development. The company’s focus on customer needs and its ability to bring new products to market quickly have resulted in strong financial performance and shareholder value.
– AstraZeneca PLC ($LSE:AZN)
AstraZeneca PLC is a pharmaceutical company with a market cap of 152.81 billion as of 2022. The company has a return on equity of -0.94%. AstraZeneca PLC is engaged in the research, development, manufacture, and marketing of prescription pharmaceuticals and biologic products for the treatment of cardiovascular, gastrointestinal, infection, neuroscience, oncology, and respiratory diseases.
Pfizer Inc reported its earnings results for the second quarter of FY2023, with total revenues of USD 12.7 billion, a decrease of 54.1% from the same quarter in the prior year. Net income was USD 2.3 billion, a 76.5% decrease from the same period in the prior year. These results show that investing in Pfizer Inc is not a great option currently, given the drastic decrease in both revenue and net income. It may be best to wait until further data is available to determine if the company is improving or not.